S. Hamdy

发表

Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients.

M. Hiratsuka, M. Mizugaki, J. Goto, 2002, Drug metabolism and pharmacokinetics.

PHARMACOKINETICS AND DISPOSITION

M. Hiratsuka, M. Mizugaki, Y. Kishikawa, 2002 .

Nanotechnology for Cancer Vaccine Delivery

A. Alshamsan, S. Hamdy, J. Samuel, 2009 .

Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity.

A. Alshamsan, A. Lavasanifar, S. Hamdy, 2008, Vaccine.

Allele and genotype frequencies of polymorphic DCP1, CETP, ADRB2, and HTR2A in the Egyptian population

M. Hiratsuka, M. Mizugaki, K. Narahara, 2002, European Journal of Clinical Pharmacology.

Development of a poly(d,l-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: implication for cancer immunotherapy.

R. Lai, A. Lavasanifar, A. Mahmud, 2010, Molecular pharmaceutics.

Detection of angiotensin-converting enzyme insertion/deletion polymorphisms using real-time polymerase chain reaction and melting curve analysis with SYBR Green I on a GeneAmp 5700.

M. Hiratsuka, M. Mizugaki, Y. Tomioka, 2001, Analytical biochemistry.

Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population.

M. Hiratsuka, M. Mizugaki, K. Narahara, 2003, British journal of clinical pharmacology.

Immunoadjuvant activity of the nanoparticles’ surface modified with mannan

A. Lavasanifar, S. Hamdy, A. Haddadi, 2014, Nanotechnology.

Effect of spironolactone on diabetic nephropathy in albino rats: ultrastructural and immunohistochemical study

Hoda Atef, Hassan M. Rezk, S. Hamdy, 2017 .

Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population.

M. Hiratsuka, M. Mizugaki, K. Narahara, 2003, British journal of clinical pharmacology.

Activation of Antigen-Specific T Cell-Responses by Mannan-Decorated PLGA Nanoparticles

A. Lavasanifar, A. Shayeganpour, S. Hamdy, 2011, Pharmaceutical Research.

Pharmaceutical analysis of synthetic lipid A-based vaccine adjuvants in poly (D,L-lactic-co-glycolic acid) nanoparticle formulations.

Vishwanatha Somayaji, S. Hamdy, A. Haddadi, 2007, Journal of pharmaceutical and biomedical analysis.

The Immunosuppressive Activity of Polymeric Micellar Formulation of Cyclosporine A: In Vitro and In Vivo Studies

A. Alshamsan, Hamidreza Montazeri Aliabadi, A. Lavasanifar, 2011, The AAPS Journal.

“Pathogen-Mimicking” Nanoparticles for Vaccine Delivery to Dendritic Cells

S. Hamdy, Praveen Elamanchili, M. Diwan, 2007, Journal of immunotherapy.

STAT3 silencing in dendritic cells by siRNA polyplexes encapsulated in PLGA nanoparticles for the modulation of anticancer immune response.

A. El-Kadi, H. Uludaǧ, A. Alshamsan, 2010, Molecular pharmaceutics.

Active targeting of dendritic cells with mannan-decorated PLGA nanoparticles

John Samuel, Afsaneh Lavasanifar, Azita Haddadi, 2011, Journal of drug targeting.

Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.

M. Hiratsuka, M. Mizugaki, K. Narahara, 2002, British journal of clinical pharmacology.

The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine.

A. El-Kadi, H. Uludaǧ, A. Alshamsan, 2010, Biomaterials.

Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations.

A. Lavasanifar, S. Hamdy, A. Haddadi, 2011, Advanced drug delivery reviews.

STAT3 Knockdown in B16 Melanoma by siRNA Lipopolyplexes Induces Bystander Immune Response In Vitro and In Vivo.

A. El-Kadi, H. Uludaǧ, A. Alshamsan, 2011, Translational oncology.

STAT 3 Knockdown in B 16 Melanoma by siRNA Lipopolyplexes Induces Bystander Immune Response In Vitro and In Vivo 1

A. El-Kadi, A. Alshamsan, A. Lavasanifar, 2011 .

Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D,L-lactic-co-glycolic acid) nanoparticles.

A. Alshamsan, T. Satou, S. Hamdy, 2007, Journal of biomedical materials research. Part A.

Immunomodulatory and anticancer effects of intra-tumoral co-delivery of synthetic lipid A adjuvant and STAT3 inhibitor, JSI-124

A. Lavasanifar, S. Hamdy, Zengshuan Ma, 2009, Immunopharmacology and immunotoxicology.

Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI‐124 in a mouse melanoma tumor model

R. Lai, A. Lavasanifar, S. Hamdy, 2008, Immunology and cell biology.

Part I: targeted particles for cancer immunotherapy.

A. Lavasanifar, S. Hamdy, A. Haddadi, 2011, Current drug delivery.

Development of a sensitive and specific liquid chromatography/mass spectrometry method for the quantification of cucurbitacin I (JSI-124) in rat plasma.

G. Kwon, D. Brocks, A. Lavasanifar, 2006, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population.

M. Hiratsuka, M. Mizugaki, Y. Kishikawa, 2002 .

Active targeting of dendritic cells with mannan-decorated PLGA nanoparticles

A. Lavasanifar, S. Hamdy, A. Haddadi, 2011, Journal of drug targeting.

PHARMACOKINETICS A ND D ISPOSITION

Y. Takekuma, K. Narahara, Tomoko Inoue, 2002 .

Biocompatible chitosan nanoparticles as an efficient delivery vehicle for Mycobacterium tuberculosis lipids to induce potent cytokines and antibody response through activation of T cells in mice

John Samuel, Afsaneh Lavasanifar, Azita Haddadi, 2014 .

Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity.

A. Alshamsan, A. Lavasanifar, S. Hamdy, 2008, Vaccine.